xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

409

Orlandi et al.

(Continues)

Nasal endoscopy scores were significantly improved in the

erythromycin group

compared to the placebo group.

SNOT-20 significantly decreased in both groups.

The SCT was shortened in more patients in the Chinese herbal

medicine group than in patients in the

erythromycin group.

No significant difference between the groups.

SNOT The intervention group showed a statistically significant improvement in

SNOT-22 scores

compared with controls.

Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Deng 1114 2018 2 RCT CRSsNP (n = 32), CRSwNP (n = 42)

Inflammatory parameters in nasal secretion, SNOT-20, VAS, olfaction, SCT, endoscopy score

SNOT-20, endoscopy, SCT, bacterial culture rate

SNOT-22,VAS,CT score, endoscopic score

Jiang 1112 2012 2 RCT Chinese herb medicine with erythromycin placebo (n = 26) Erythromycin 250 mg (n = 27) q12H for 8 weeks.

2. Control: fluticasone nasal spray postoperatively (n = 44)

Haxel 1116 2015 2 RCT CRSsNP or CRSwNP after ESS 1.Erythromycin 250 mg daily (n = 29) 2.Placebo (n = 29) for 3 months Amali 1115 2014 2 RCT CRSsNP (n (n = 28).

= 38) and CRSwNP

1. Azithromycin postoperatively 250 mg daily and fluticasone nasal spray for 3 months (n = 22)

1. Clarithromycin 0.25 g/d and budesonide nasal spray 256 μ g/d) for 3 months

2. Budesonide nasal spray 256 μ g/d.

TABLE IX-31 (Continued)